GenScript Achieves MSCI ESG A Rating for Sustainability Progress

  • GenScript receives MSCI ESG A rating upgrade for its sustainability efforts.

GenScript Biotech Corporation has been upgraded to an A rating in its Environmental, Social, and Governance (ESG) score by MSCI, a globally respected rating agency.

MSCI evaluates thousands of companies globally, assessing their ESG performance and risk management. The agency’s ratings are widely regarded in international financial markets. GenScript’s improved rating is a recognition of the company’s progress over the past year in areas such as corporate governance, product safety, and environmental protection.

The company has taken several steps to enhance its ESG management, including forming a dedicated ESG team and collaborating with research institutions worldwide. “The A rating from MSCI is a significant recognition of our improvement in ESG performance,” said Sherry Shao, Rotating CEO of GenScript. “We believe integrating ESG principles strengthens our resilience and supports long-term success.”

In 2024, GenScript advanced its ESG commitments by joining the Science Based Targets initiative (SBTi) and submitting carbon reduction targets to address climate change. The company also received a bronze rating from EcoVadis for its supply chain management and workplace practices.

Experience the future of contract manufacturing

Join us at CDMO Live, 7-8 May 2025 in Rotterdam for an exclusive live event dedicated to contract manufacturing partnerships. Apply for your ticket.

Sign up to our free weekly newsletter for all the latest contract manufacturing news.  Register here

ELEARNING

Learn the essentials of successful biopharma outsourcing

New eLearning course distils 100+ expert interviews into 10 engaging modules.

tick Overview of outsourcing trends 
tick Expert insights and case studies 
tick Helpful resources and quizzes

Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.